Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Moolec Science ( (MLEC) ) has shared an announcement.
Moolec Science SA, a company involved in a business combination with Bioceres Group Limited, Gentle Technologies Corp, and Nutrecon LLC, has undergone significant changes, including a reverse stock split and redomiciliation from Luxembourg to the Cayman Islands. On June 16, 2025, Moolec completed a business combination, becoming the legal parent of the combined group. However, the company faces financial challenges as Bioceres Crop Solutions Corp, a subsidiary, lost de facto control, leading to its deconsolidation. This has restricted access to financing for Moolec and its subsidiaries, raising uncertainties about their ability to continue as a going concern. Efforts are underway to restructure Bioceres S.A.’s debt, but the outcome remains uncertain.
The most recent analyst rating on (MLEC) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Moolec Science stock, see the MLEC Stock Forecast page.
Spark’s Take on MLEC Stock
According to Spark, TipRanks’ AI Analyst, MLEC is a Underperform.
Moolec Science faces significant financial challenges with negative profitability and cash flow issues despite revenue growth. The technical analysis is bearish, and the valuation appears unfavorable with a negative P/E ratio. These factors contribute to a low overall stock score, highlighting the need for improved financial performance and market sentiment.
To see Spark’s full report on MLEC stock, click here.
More about Moolec Science
Average Trading Volume: 66,792
Technical Sentiment Signal: Sell
Current Market Cap: $10.91M
Learn more about MLEC stock on TipRanks’ Stock Analysis page.